Subscribe
shutterstock-3011837-web
Laurin Rinder / Shutterstock.com
23 July 2014Big Pharma

Court denies Lilly’s application to block GSK SPC

The English High Court has dismissed an application by Eli Lilly to stop Human Genome Sciences (HGS) from receiving a supplementary protection certificate (SPC) based on a marketing authorisation Lilly may receive for a new drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK avoids $57m damages award over royalties
4 March 2021   GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
GSK avoids $57m damages award over royalties
4 March 2021   GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.

More on this story

Big Pharma
GSK avoids $57m damages award over royalties
4 March 2021   GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York